Long-term ADHD treatment increases brain dopamine transporter levels, may affect drug efficacy

12-month treatment may impact adult ADHD patients' response to methylphenidate

2013-05-16

(Press-News.org) Long-term treatment of attention deficit/hyperactivity disorder (ADHD) with certain stimulant medications may alter the density of the dopamine transporter, according to research published May 15 in the open access journal PLOS ONE by Gene-Jack Wang and colleagues from Brookhaven National Laboratory and the intramural program at NIH.

ADHD is commonly treated using drugs to target dysfunctional dopamine signaling in the brain, such as methylphenidate (commonly known as Ritalin). The researchers found that adults with ADHD who had been prescribed the drug methylphenidate for a period of 12 months had a 24% increase in the density of the dopamine transporter in some brain regions, which after treatment was significantly higher than in adults without ADHD who had not been treated with the drug. Prior to the 12-month treatment, there were no significant differences in the two groups' dopamine transporter levels. The authors conclude that the elevated dopamine transporter density, suggested by some as a biological test for diagnosis of ADHD, may be a consequence of chronic treatment rather than a marker for the disorder. These findings may offer an explanation for discrepancies in the literature describing dopamine transporter levels in ADHD patients, as differences in dopamine transporter levels in the brain may be due to differences in prior treatment.

Many studies have shown that an acute increase in dopamine signaling while on methylphenidate treatment can improve ADHD symptoms in the short term, but this is the first study to analyze the long-term effects of treatment.

### Citation: Wang G-J, Volkow ND, Wigal T, Kollins SH, Newcorn JH, et al. (2013) Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder. PLoS ONE 8(5): e63023. doi:10.1371/journal.pone.0063023

Financial Disclosure: The work was supported by the National Institutes of Health: R01MH66961 to Dr. GJW. The PET study was carried out at Brookhaven National Laboratory with infrastructure support from the U.S. Department of Energy Office of Biological and Environmental Research (DE-ACO2-76CH00016), M01RR10710 (the General Clinical Research Center of Stony Brook University). An Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism (Z01AA000550) supported Drs. NDV and FT and Mr. MJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interest Statement: Dr. GJW received research funding from the Orexigen Therapeutics Inc.; Dr. NDV reports no competing interests; Dr. TW reports no competing interests; Dr. SHK reports no competing interests; Dr. JHN reports no competing interests; Dr. FT reports no competing interests; Dr. JL reports no competing interests; Mr. MJ reports no competing interests; Mr. CTW reports no competing interests; Mr. HH reports no competing interests; Dr. JSF reports no competing interests; Dr. WZ reports no competing interests; Dr. JMS reports no competing interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

PLEASE LINK TO THE SCIENTIFIC ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL goes live after the embargo ends): http://dx.plos.org/10.1371/journal.pone.0063023

Disclaimer: This press release refers to upcoming articles in PLOS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information. About PLOS ONE: PLOS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLOS ONE is published by the Public Library of Science (PLOS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.

All works published in PLOS ONE are Open Access. Everything is immediately available—to read, download, redistribute, include in databases and otherwise use—without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLOS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.plos.org/media.

ELSE PRESS RELEASES FROM THIS DATE:

First prospective trial shows molecular profiling timely for tailoring therapy

2013-05-16

WASHINGTON — A clinical trial has shown that patients, and their physicians, are eager to jump into next-era cancer care — analysis of an individual's tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology years before investigators thought they would be ready. CUSTOM is the first completed prospective clinical trial that used genetic analysis alone to assign cancer treatment for patients with one of three different cancers. "We expected ...

Preclinical tests shows agent stops 'slippery' proteins from binding, causing Ewing sarcoma

2013-05-16

WASHINGTON — Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study, which will be presented at the 2013 annual meeting of the American Society of Clinical Oncology, provides pre-clinical evidence necessary to initiate a clinical trial. "This agent has the potential to be more effective, and considerably less toxic, than the current drugs now used to ...

Frogs in California harbor deadly amphibian pathogen, Stanford researchers find

2013-05-16

STANFORD, Calif. - In a new study, Stanford University School of Medicine researchers provide the first evidence that African clawed frogs in California harbor a deadly fungal infection that is decimating amphibian populations across the globe. Among 28 samples tested, the researchers identified three frogs, including one found in Golden Gate Park in San Francisco, that were carriers of the pathogen that has led to the decline or extinction of some 200 amphibian species worldwide. The research was conducted on archived samples from the herpetology collection at the California ...

Cancer diagnosis puts people at greater risk for bankruptcy

2013-05-16

SEATTLE – People diagnosed with cancer are more than two-and-a-half times more likely to declare bankruptcy than those without cancer, according to a new study from Fred Hutchinson Cancer Research Center. Researchers also found that younger cancer patients had two- to five-fold higher bankruptcy rates compared to older patients, and that overall bankruptcy filings increased as time passed following diagnosis. The study, led by corresponding author Scott Ramsey, M.D., Ph.D., an internist and health economist at Fred Hutch, was published online on May 15 as a Web First in ...

Study finds disagreement on the role of primary care nurse practitioners

2013-05-16

At a time when the U.S. health system is facing both an increasing demand for primary care services and a worsening shortage of primary care physicians, one broadly recommended strategy has been to increase the number and the responsibilities of nurse practitioners. In 2010 an Institute of Medicine (IOM) committee recommended that "advance practice registered nurses should be able to practice to the full extent of their education and training" and that nurse practitioners should be able to admit patients to hospitals and hospices, lead medical teams and medical homes, and ...

Getting fit in middle age can reduce heart failure risk

2013-05-16

Middle aged and out of shape? It's not too late to get fit — and reduce your risk for heart failure, according to research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013. Researchers ranked fitness levels of 9,050 men and women (average age 48) who took two fitness tests — eight years apart — during mid-life. After 18 years of follow-up, they matched the fitness information to Medicare claims for heart failure hospitalizations. "People who weren't fit at the start of the study were at higher risk for heart ...

Young women often less healthy than young men before heart attacks

2013-05-16

Young women tend to be less healthy and have a poorer quality of life than similar-aged men before suffering a heart attack, according to research presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013. "Compared with young men, women under 55 years are less likely to have heart attacks. But, when they do occur, women are more likely to have medical problems, poorer physical and mental functioning, more chest pain and a poorer quality of life in the month leading up to their heart attack," said Rachel Dreyer, Ph.D., ...

H1N1 discovered in marine mammals

2013-05-16

Scientists at the University of California, Davis, detected the H1N1 (2009) virus in free-ranging northern elephant seals off the central California coast a year after the human pandemic began, according to a study published today, May 15, in the journal PLOS ONE. It is the first report of that flu strain in any marine mammal. "We thought we might find influenza viruses, which have been found before in marine mammals, but we did not expect to find pandemic H1N1," said lead author Tracey Goldstein, an associate professor with the UC Davis One Health Institute and ...

Catching graphene butterflies

2013-05-16

Writing in Nature, a large international team led Dr Roman Gorbachev from The University of Manchester shows that, when graphene placed on top of insulating boron nitride, or 'white graphene', the electronic properties of graphene change dramatically revealing a pattern resembling a butterfly. The pattern is referred to as the elusive Hofstadter butterfly that has been known in theory for many decades but never before observed in experiments. Combining graphene with other materials in multiple-layered structures could lead to novel applications not yet explored by ...

Billion-year-old water could hold clues to life on Earth and Mars

2013-05-16

A UK-Canadian team of scientists has discovered ancient pockets of water, which have been isolated deep underground for billions of years and contain abundant chemicals known to support life. This water could be some of the oldest on the planet and may even contain life. Not just that, but the similarity between the rocks that trapped it and those on Mars raises the hope that comparable life-sustaining water could lie buried beneath the red planet's surface. The findings, published in Nature today, may force us to rethink which parts of our planet are fit for life, ...

Long-term ADHD treatment increases brain dopamine transporter levels, may affect drug efficacy

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: